Avadel Completes Enrollment in Phase 3 LUMRYZ Trial

Avadel Pharmaceuticals ( (AVDL) ) has shared an announcement.

On December 18, 2025, Avadel Pharmaceuticals announced it had completed patient enrollment in REVITALYZ, its Phase 3 double-blind, placebo-controlled, randomized withdrawal trial of once-at-bedtime LUMRYZ (sodium oxybate) for idiopathic hypersomnia, a rare and severely debilitating sleep disorder affecting an estimated 40,000 diagnosed patients in the U.S. The trial, which includes both patients transitioning from immediate-release oxybates and those naïve to oxybate therapy, is designed to measure reductions in daytime sleepiness via the Epworth Sleepiness Scale at Week 14, alongside secondary endpoints on symptom severity, functional outcomes, and patient and clinician impressions of change; successful results could extend LUMRYZ’s footprint beyond narcolepsy into idiopathic hypersomnia, reinforcing Avadel’s position in the sleep-disorder market and potentially offering a once-nightly alternative in an underserved therapeutic area.

The most recent analyst rating on (AVDL) stock is a Hold with a $22.50 price target. To see the full list of analyst forecasts on Avadel Pharmaceuticals stock, see the AVDL Stock Forecast page.

Spark’s Take on AVDL Stock

According to Spark, TipRanks’ AI Analyst, AVDL is a Neutral.

Avadel Pharmaceuticals’ overall stock score is driven by strong corporate events and positive technical indicators. However, the company’s financial performance is hindered by profitability challenges, and its valuation is impacted by a negative P/E ratio. The stock shows potential for growth, supported by strategic corporate actions and positive market momentum.

To see Spark’s full report on AVDL stock, click here.

More about Avadel Pharmaceuticals

Avadel Pharmaceuticals plc is a Dublin-based biopharmaceutical company listed on Nasdaq that focuses on developing and commercializing extended-release medicines, notably LUMRYZ, an FDA-approved once-at-bedtime sodium oxybate oral suspension for treating cataplexy and excessive daytime sleepiness in adults and pediatric patients aged seven and older with narcolepsy. LUMRYZ holds multiple U.S. orphan drug exclusivities and is positioned as a clinically superior, single-nightly alternative to twice-nightly oxybate therapies, underscoring Avadel’s focus on rare, debilitating sleep disorders with significant unmet medical need.

Average Trading Volume: 2,906,643

Technical Sentiment Signal: Buy

Current Market Cap: $2.09B

Find detailed analytics on AVDL stock on TipRanks’ Stock Analysis page.